| Literature DB >> 26950852 |
Clancy J Clark1, Shahzad M Ali2, Victor Zaydfudim3, Adam K Jacob4, David M Nagorney2.
Abstract
BACKGROUND: Enhanced recovery pathways (ERP) have not been widely implemented for hepatic surgery. The aim of this study was to evaluate the safety of an ERP for patients undergoing open hepatic resection.Entities:
Mesh:
Year: 2016 PMID: 26950852 PMCID: PMC4780831 DOI: 10.1371/journal.pone.0150782
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Enhanced Recovery Pathway after Hepatic Resection.
| Preoperative education regarding the operation and expected recovery. | ||
| Omission of bowel preparation. | ||
| Preoperative medication with gabapentin, celecoxib, and acetaminophen. | ||
| Standardized anesthetic with intrathecal analgesia. | ||
| Routine postoperative antiemetics. | ||
| Discontinuation of nasogastric tube before leaving the operating room. | ||
| Ketorolac/Ibuprofen and acetaminophen with supplemental oral narcotic, starting night of operation. | ||
| General diet with clear liquid oral nutritional supplement, starting night of operation. | ||
| Enforced ambulation and in chair for all meals, starting night of operation. | ||
| Foley catheter removal, day after operation. | ||
| Minimal intravenous fluids and saline lock, day after operation. | ||
| Venous thromboembolism prophylaxis. | ||
| Standardized bowel regimen. | ||
| Standardized laboratory tests. |
Comparison of clinical characteristics between Pre- ERP vs. ERP groups.
| Variable | Overall (n = 126) | Pre-ERP (n = 73) | ERP (n = 53) | p-value |
|---|---|---|---|---|
| Age, median (IQR) | 62 (50–72) | 65 (51–73) | 59 (47–68) | 0.114 |
| Male Sex, No. (%) | 58 (46.0) | 36 (49.3) | 22 (41.5) | 0.470 |
| ASA, No. (%) | ||||
| I | 4 (3.2) | 3 (4.1) | 1 (1.9) | 0.709 |
| II | 71 (56.4) | 42 (57.5) | 29 (54.7) | |
| III | 51 (40.5) | 28 (38.4) | 23 (43.4) | |
| Comorbidity, No. (%) | ||||
| Chronic Renal Failure | 5 (4.0) | 3 (4.1) | 2 (3.8) | >0.999 |
| Diabetes Mellitus | 24 (19.1) | 13 (17.8) | 11 (20.8) | 0.819 |
| Coronary Artery Disease | 8 (6.4) | 6 (8.2) | 2 (3.8) | 0.466 |
| Obesity, BMI > 30, No. (%) | 46 (36.5) | 24 (32.9) | 22 (41.5) | 0.353 |
| COPD | 6 (4.8) | 4 (5.5) | 2 (3.8) | >0.999 |
| Alcohol Abuse, No. (%) | 15 (11.9) | 10 (13.7) | 5 (9.4) | 0.582 |
| History of Tobacco Use, No. (%) | 68 (54.0) | 38 (52.1) | 30 (56.6) | 0.718 |
| Prior Abdominal Operation, No. (%) | 96 (76.2) | 53 (72.6) | 43 (81.1) | 0.297 |
| Prior Hepatic Resection, No. (%) | 16 (12.7) | 7 (9.6) | 9 (17.0) | 0.281 |
| Liver Disease, No. (%) | ||||
| Hepatitis B | 1 (0.8) | 1 (1.4) | 0 (0) | >0.999 |
| Hepatitis C | 3 (2.4) | 1 (1.4) | 2 (3.8) | 0.572 |
| Cirrhosis | 3 (2.4) | 2 (2.7) | 1 (1.9) | >0.999 |
| Primary Sclerosing Cholangitis | 2 (1.6) | 1 (1.4) | 1 (1.9) | >0.999 |
| Indication for Operation, No. (%) | ||||
| Colorectal Metastases | 42 (33.3) | 22 (30.1) | 20 (37.7) | 0.317 |
| Cholangiocarcinoma | 20 (15.9) | 14 (19.2) | 6 (11.3) | |
| Hepatocellular Carcinoma | 18 (14.3) | 8 (11.0) | 10 (18.9) | |
| Benign Primary Liver Tumor | 16 (12.7) | 12 (16.4) | 4 (7.6) | |
| Neuroendocrine Metastases | 13 (10.3) | 8 (11.0) | 5 (9.4) | |
| Gallbladder Carcinoma | 8 (3.4) | 3 (4.1) | 5 (9.4) | |
| Other | 9 (7.1) | 6 (8.2) | 3 (5.7) |
MELD, Model for End Stage Liver Disease; COPD, Chronic Obstructive Pulmonary Disease; IQR, Interquartile Range; ASA, American Society of Anesthesiologists; ERP, enhanced recovery pathway
* Other included hemangioma n = 6, intrahepatic biliary benign stricture n = 1, indeterminate intrahepatic fibrous tumor n = 1, and primary hepatic neuroendocrine tumor n = 1.
Comparison of operative details between Pre-ERP vs. ERP groups.
| Variable | Overall (n = 126) | Pre-ERP (n = 73) | ERP (n = 53) | p-value |
|---|---|---|---|---|
| Major Hepatic Liver Resection, No. (%) | 47 (37.3) | 30 (41.1) | 17 (32.1) | 0.353 |
| Procedure, No. (%) | ||||
| Subsegmentectomy | 22 (17.5) | 13 (17.8) | 9 (17.0) | 0.861 |
| Multiple Subsegmentectomies | 30 (23.8) | 16 (21.9) | 14 (26.4) | |
| Single Segmentectomy | 9 (7.1) | 5 (6.9) | 4 (7.6) | |
| Multiple Segments | 24 (19.1) | 12 (16.4) | 12 (22.6) | |
| Hepatectomy | 29 (23.0) | 19 (26.0) | 10 (18.9) | |
| Extended Hepatectomy | 12 (9.5) | 8 (11.0) | 4 (7.6) | |
| Vascular Resection or Repair, No. (%) | 5 (4.0) | 3 (4.1) | 2 (3.8) | >0.999 |
| Radiofrequency Ablation, No. (%) | 18 (14.3) | 10 (13.7) | 8 (15.1) | >0.999 |
| Estimated Blood Loss, ml, median (IQR) | 400 (150–650) | 400 (150–600) | 350 (200–700) | 0.812 |
| Intraoperative Blood Transfusion, No. (%) | 17 (13.5) | 11 (15.1) | 6 (11.3) | 0.606 |
| Intraoperative IV Fluids, ml, median (IQR) | 3000 (2250–4000) | 3000 (2000–4000) | 3500 (2500–4100) | 0.044 |
| Transfer to ICU Immediately After Operation, No. (%) | 8 (6.4) | 4 (5.5) | 4 (7.6) | 0.720 |
IQR, Interquartile Range; ICU, Intensive Care Unit; ERP, Enhanced Recovery Pathway
Comparison of postoperative outcomes between Pre- ERP vs. ERP groups.
| Variable | Overall (n = 126) | Pre-ERP (n = 73) | ERP (n = 53) | p-value |
|---|---|---|---|---|
| Length of Stay, days, median (IQR) | 5 (4–7) | 5 (4–7) | 5 (4–6) | 0.708 |
| Postoperative Blood Transfusion, No. (%) | 4 (3.2) | 2 (2.7) | 2 (3.8) | >0.999 |
| Percutaneous Drainage, No. (%) | 5 (4.0) | 4 (5.5) | 1 (1.9) | 0.397 |
| Reoperation, No. (%) | 4 (3.2) | 2 (2.7) | 2 (3.8) | >0.999 |
| Unplanned Postoperative ICU Transfer, No. (%) | 14 (11.1) | 10 (13.7) | 4 (7.6) | 0.392 |
| Readmission, 90-day, No. (%) | 4 (3.2) | 2 (2.7) | 2 (3.8) | >0.999 |
| Any Complication, No. (%) | 42 (33.3) | 27 (37.0) | 15 (28.3) | 0.343 |
| Complication Severity Score, No. (%) | ||||
| None | 84 (66.7) | 46 (63.0) | 38 (71.7) | 0.476 |
| Mild | 16 (12.7) | 8 (11.0) | 8 (15.1) | |
| Moderate | 16 (12.7) | 11 (15.1) | 5 (9.4) | |
| Severe | 9 (7.1) | 7 (9.6) | 2 (3.8) | |
| Death | 1 (0.8) | 1 (1.4) | 0 (0) |
IQR, Interquartile Range; ICU, intensive care unit; ERP, Enhanced Recovery Pathway
Comparison of specific postoperative complications between Pre- ERP vs. ERP groups.
No significant differences between individual complications were identified (all p-values > 0.1).
| Complication | Overall (n = 126) | Pre-ERP (n = 73) | ERP (n = 53) |
|---|---|---|---|
| Acute Renal Failure | 5 (4.0) | 3 (4.1) | 2 (3.8) |
| Bile Leak | 6 (4.8) | 5 (6.9) | 1 (1.9) |
| Deep Venous Thrombosis | 4 (3.2) | 3 (4.1) | 1 (1.9) |
| Pulmonary Embolism | 3 (2.4) | 2 (2.7) | 1 (1.9) |
| Intra-abdominal Bleeding | 3 (2.4) | 1 (1.4) | 2 (3.8) |
| Hepatic Insufficiency | 3 (2.4) | 3 (4.1) | 0 (0) |
| Ileus | 8 (6.4) | 5 (6.9) | 3 (5.7) |
| Pneumonia | 6 (4.8) | 5 (6.9) | 1 (1.9) |
| Respiratory failure requiring intubation | 4 (3.2) | 4 (5.5) | 0 (0) |
| Septic Shock | 1 (0.8) | 1 (1.4) | 0 (0) |
| Superficial Skin Infection | 2 (1.6) | 0 (0) | 2 (3.8) |
| Cardiac Dysrhythmia | 5 (4.0) | 3 (4.1) | 2 (3.8) |
*Other complications not listed include severe postoperative delirium (n = 1), chylous ascites (n = 1), and failure to thrive requiring total parental nutrition (n = 1). Complications due to myocardial infection, bacteremia, or intra-abdominal abscess unrelated to bile leak were not identified during the study period